Business Wire

THE-EARTHSHOT-PRIZE

17.10.2021 22:02:10 CEST | Business Wire | Press release

Share
First-ever Winners of Prince William’s Earthshot Prize announced at star-studded London Awards Ceremony

The Earthshot Prize has tonight revealed the first-ever five Winners at a glittering ceremony held in London. Each Winner will receive £1million prize money and a global network of support to scale their cutting-edge environmental solutions to repair our planet.

The five Winners, which span the globe from Costa Rica to India, include transformative technologists, innovators, an entire country, and a pioneering city and were chosen for their ground-breaking solutions to the greatest environmental challenges facing our planet.

Earthshot Prize Founder and Prize Council Member Prince William said:

“Our five inspirational Winners show that everyone has a role to play in the global effort to repair our planet. We need businesses, leaders, innovators, and communities to take action. And, ultimately, we need all of us to demand that the solutions get the support they need. Because the success of our Winners is our collective, global Earthshot.”

Earthshot Prize Council Member Sir David Attenborough said:

“The natural world on which we entirely depend is declining at a rate faster than at any time since the end of the dinosaurs. We know where this story is heading and we must now write a different ending. This is what The Earthshot Prize was created to achieve. The 15 Earthshot Prize Finalists tonight build optimism by finding innovative and brilliant solutions to the world’s challenges, and they give us hope, which, we are told, springs eternal.”

The Earthshot Prize Winners for 2021 are:

  • Protect and Restore Nature: The Republic of Costa Rica
    • With an innovative policy paying citizens to protect the rainforests and restore local ecosystems, the people of Costa Rica and their Ministry for Environment have reversed decades of deforestation. Since the programme launched, Costa Rica’s forests have doubled in size, leading to a boom in ecotourism and contributing $4 billion to the economy
    • Through winning The Earthshot Prize, Costa Rica will expand their work to protect the ocean and support the replication of their approach in other countries, especially in the Global South.
  • Clean our Air: Takachar, India
    • New Delhi-based Takachar has developed pioneering technology to help end the burning of agricultural waste, which causes severe air pollution. Their cheap, small-scale, portable technology attaches to tractors and converts crop residues into sellable products like fuel and fertilizer and helps reduce smoke emissions by up to 98%.
    • By winning The Earthshot Prize, Takachar will expand its operations to more rural communities around the world with a goal to cut a billion tonnes of carbon dioxide a year.
  • Revive our Oceans: Coral Vita, Bahamas
    • Coral Vita’s innovative approach to coral farming of growing coral on land then replanting it in the ocean can grow coral up to 50 times faster than traditional methods and improves coral resilience to the impact of climate change.
    • Winning The Earthshot Prize will accelerate Coral Vita’s goal to establish a global network of coral farms to grow a billion corals each year.
  • Build a Waste-free World: The City of Milan Food Waste Hubs, Italy
    • As the first major city to enforce a city-wide food waste policy, Milan’s Food Waste Hub programme recovers food from local supermarkets and restaurants and distributes it to citizens in need, recovering about 130 tonnes of food per year, an estimated 260,000 meals equivalent.
    • Through winning The Earthshot Prize, the city of Milan’s model can be scaled to other cities.
  • Fix our Climate: AEM Electrolyser, Thailand/Germany/Italy
    • The AEM Electrolyser from Enapter turns renewable electricity into emission-free hydrogen gas with a technology that has been developed quicker and cheaper than ever before and can transform how we power our homes and buildings and fuel transport.
    • Funding from The Earthshot Prize will help scale mass production, making it universally easy to buy and install AEM Electrolysers wherever activities have high energy demand.

The ceremony capped a 10-month global search with over 750 applications from around the world. 15 Finalists were chosen through a rigorous selection process, supported by an Expert Advisory Panel, for their potential to positively impact people and the natural world and their ability to help us reach our Earthshot goals.

The five Winners were selected by The Earthshot Prize Council, a diverse team of influential individuals which includes: HRH Prince William, Her Majesty Queen Rania Al Abdullah of Jordan, Sir David Attenborough, Dr Ngozi Okonjo-Iweala, Indra Nooyi, Shakira Mebarak, Christiana Figueres, Luisa Neubauer, Cate Blanchett, Yao Ming, Daniel Alves Da Silva, Ernest Gibson, Hindou Oumarou Ibrahim, Jack Ma, and Naoko Yamazaki.

The Winners were connected to the Awards Ceremony by global broadcast, where The Duke and Duchess of Cambridge were joined by Sir David Attenborough, Christiana Figueres, Dani Alves and a host of stars and performers including Ed Sheeran and Yemi Alade.

All 15 Finalists will receive tailored support from The Earthshot Prize Global Alliance, an unrivalled network of philanthropies, NGOs, and private sector businesses around the world who will help scale their solutions.

The Awards Ceremony concluded by revealing The Earthshot Prize will travel to the United States of America in 2022. Nominations for the 2022 Prize will open in January 2022.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye